Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)

BACKGROUND: A phase 3 study to assess the efficacy and safety of the desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, against the epoetin alfa for the treatment of anemia in patients with chronic kidney disease (CKD) with dialysis dependency. METHODS: DREAM-D was a phase 3,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gang, Sishir, Khetan, Prakash, Varade, Deepak, Chinta, Venkata Ramakrishna, Mavani, Siddharth, Gupta, Umesh, Reddy, S. Venkata Krishna, Rajanna, Sunil, Jeloka, Tarun, Ruhela, Vivek, Kansagra, Kevinkumar, Kanani, Pooja, Bhatt, Jayesh, Zala, Kuldipsinh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Patient-Oriented, Translational Research: Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254304/
https://www.ncbi.nlm.nih.gov/pubmed/35462369
http://dx.doi.org/10.1159/000523949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254304/
https://www.ncbi.nlm.nih.gov/pubmed/35462369
http://dx.doi.org/10.1159/000523949

Ejemplares similares